Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.

Autor: Payne AB; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: bvx2@cdc.gov., Watts JA; Westat, Rockville, MD, USA., Mitchell PK; Westat, Rockville, MD, USA., Dascomb K; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA., Irving SA; Kaiser Permanente Center for Health Research, Portland, OR, USA., Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Grannis SJ; Indiana University School of Medicine, Indianapolis, IN, USA; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA., Ong TC; University of Colorado School of Medicine, Aurora, CO, USA., Ball SW; Westat, Rockville, MD, USA., DeSilva MB; HealthPartners Institute, Minneapolis, MN, USA., Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA., Sheffield T; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA., Bride D; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA., Arndorfer J; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA., Naleway AL; Kaiser Permanente Center for Health Research, Portland, OR, USA., Koppolu P; Kaiser Permanente Center for Health Research, Portland, OR, USA., Fireman B; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Zerbo O; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Timbol J; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Goddard K; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Dixon BE; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Health Policy and Management, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA., Fadel WF; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Biostatistics and Health Data Science, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA., Rogerson C; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, IN, USA., Allen KS; Regenstrief Institute Center for Biomedical Informatics, Indianapolis, IN, USA; Department of Health Policy and Management, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA., Rao S; University of Colorado School of Medicine, Aurora, CO, USA., Mayer D; University of Colorado School of Medicine, Aurora, CO, USA., Barron M; University of Colorado School of Medicine, Aurora, CO, USA., Reese SE; Westat, Rockville, MD, USA., Rowley EAK; Westat, Rockville, MD, USA., Najdowski M; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Eagle Health Analytics, San Antonio, TX, USA., Ciesla AA; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Eagle Health Analytics, San Antonio, TX, USA., Mak J; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Reeves EL; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Akinsete OO; HealthPartners Institute, Minneapolis, MN, USA., McEvoy CE; HealthPartners Institute, Minneapolis, MN, USA., Essien IJ; HealthPartners Institute, Minneapolis, MN, USA., Tenforde MW; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Fleming-Dutra KE; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Link-Gelles R; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; United States Public Health Service Commissioned Corps, Rockville, MD, USA.

Publikováno v: Lancet (London, England) [Lancet] 2024 Oct 19; Vol. 404 (10462), pp. 1547-1559.

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.

Autor: Payne AB; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: ABPayne@cdc.gov., Ciesla AA; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Eagle Health Analytics, San Antonio, TX, USA., Rowley EAK; Westat, Rockville, MD, USA., Weber ZA; Westat, Rockville, MD, USA., Reese SE; Westat, Rockville, MD, USA., Ong TC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Vazquez-Benitez G; HealthPartners Institute, Minneapolis, MN, USA., Naleway AL; Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA., Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA., Embi PJ; Vanderbilt University Medical Center, Nashville, TN, USA., Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA., Kharbanda AB; Children's Minnesota, Minneapolis, MN, USA., Gaglani M; Section of Pediatric Infectious Diseases, Center for Research in Vaccines and Infections, Baylor Scott & White Health and Baylor College of Medicine, Temple, TX, USA; Texas A&M University College of Medicine, Temple, TX, USA., Tenforde MW; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Link-Gelles R; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; United States Public Health Service Commissioned Corps, Rockville, MD, USA.

Publikováno v: Vaccine [Vaccine] 2023 Dec 12; Vol. 41 (51), pp. 7581-7586. Date of Electronic Publication: 2023 Nov 23.

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023.

Autor: Link-Gelles R, Ciesla AA, Rowley EAK, Klein NP, Naleway AL, Payne AB, Kharbanda A, Natarajan K, DeSilva MB, Dascomb K, Irving SA, Zerbo O, Reese SE, Wiegand RE, Najdowski M, Ong TC, Rao S, Stockwell MS, Stephens A, Goddard K, Martinez YC, Weber ZA, Fireman B, Hansen J, Timbol J, Grannis SJ, Barron MA, Embi PJ, Ball SW, Gaglani M, Grisel N, Arndorfer J, Tenforde MW, Fleming-Dutra KE

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Aug 18; Vol. 72 (33), pp. 886-892. Date of Electronic Publication: 2023 Aug 18.

Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.

Autor: Fleming-Dutra KE, Ciesla AA, Roper LE, Smith ZR, Miller JD, Accorsi EK, Verani JR, Shang N, Derado G, Wiegand RE, Pilishvili T, Britton A, Link-Gelles R

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Feb 17; Vol. 72 (7), pp. 177-182. Date of Electronic Publication: 2023 Feb 17.

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.

Autor: Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, Miller JD, Accorsi EK, Schrag SJ, Verani JR, Shang N, Derado G, Pilishvili T

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Dec 02; Vol. 71 (48), pp. 1526-1530. Date of Electronic Publication: 2022 Dec 02.